BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2024 7:56:29 AM | Browse: 201 | Download: 555
 |
Received |
|
2023-11-01 10:51 |
|
Peer-Review Started |
|
2023-11-01 10:52 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-04 19:23 |
|
Revised |
|
2023-12-11 09:23 |
|
Second Decision |
|
2024-01-08 03:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-01-08 08:13 |
|
Articles in Press |
|
2024-01-08 08:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-20 15:00 |
|
Publish the Manuscript Online |
|
2024-01-26 07:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Zhe Cao, Guang-Lei Zheng, Tian-Qi Zhang, Hong-Yan Shao, Jia-Yu Pan, Zi-Lin Huang and Meng-Xuan Zuo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Guangdong Province |
2020A1515011539 |
|
| Corresponding Author |
Meng-Xuan Zuo, MD, Attending Doctor, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Yuexiu District, Guangzhou 510060, Guangdong Province, China. zuomx@sysucc.org.cn |
| Key Words |
Unresectable hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Angiogenesis inhibitors; Programmed cell death protein 1; Programmed death ligand 1 |
| Core Tip |
The network meta-analysis showed the treatment based on hepatic arterial infusion chemotherapy (HAIC) had the best efficacy on unresectable hepatocellular carcinoma (uHCC). The retrospective, relatively large-scale study suggested HAIC combined with angiogenesis inhibitors and programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blockers could improve the uHCC patients’ prognosis. After propensity score matching, it demonstrated that triple therapy was able to prolong the uHCC patients’ survival than angiogenesis inhibitors and PD-1/PD-L1 blockers. |
| Publish Date |
2024-01-26 07:56 |
| Citation |
Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i4.318 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
